Log In
Print
BCIQ
Print
Print this Print this
 

USL261 (formerly ITI-111)

Also known as: Intranasal midazolam

  Manage Alerts
Collapse Summary General Information
Company Ikano Therapeutics Inc.
DescriptionIntranasal formulation of midazolam, a short-acting benzodiazepine derivative
Molecular Target GABA receptor
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationEpilepsy
Indication DetailsTreat seizure clusters
Regulatory Designation U.S. - Fast Track (Treat seizure clusters);
U.S. - Orphan Drug (Treat seizure clusters);
U.S. - Special Protocol Assessment (Treat seizure clusters)
Partner Upsher-Smith Laboratories Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today